trending Market Intelligence /marketintelligence/en/news-insights/trending/c5sbxqfuhqaockagd-vjpg2 content esgSubNav
In This List

Dermira reports positive results from phase 3 hyperhidrosis studies

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Dermira reports positive results from phase 3 hyperhidrosis studies

Dermira Inc. said two phase 3 studies linked glycopyrronium tosylate with better outcomes in pediatric patients with excessive underarm sweating.

The randomized studies, called Atmos-1 and Atmos-2, enrolled 44 patients between ages 9 and 16 with primary axillary hyperhidrosis. Overall, 463 participants received glycopyrronium tosylate, a topical wipe formerly known as DRM04, while 234 received just the neutral substance used to dissolve active ingredients, called a vehicle.

Dermira said the effect was the same between the study's pediatric and adult patient groups, with 59.9% and 60.2%, respectively, having noted improvements in their excessive underarm sweating after receiving glycopyrronium tosylate. For the vehicle-treated population, 13% and 28.8% of pediatric and adult participants, respectively, noted improvements.

Superior results for glycopyrronium tosylate were also observed in terms of sweat reduction, quality of life and safety, compared to vehicle treatment.

The Menlo Park, Calif.-based company presented the new data at the 76th Annual American Academy of Dermatology Meeting in San Diego.